Group items matching
in title, tags, annotations or url![3 Naturopathy Treatments for Obesity That Works Best](http://s3.amazonaws.com/diigo/thumbnail_160/8710315_268134682_17894292.jpg?AWSAccessKeyId=0R7FMW7AXRVCYMAPTPR2&Expires=1725619603&Signature=lyfILTqvgCEtMfR8zZMkW4v%2BUKQ%3D)
3 Naturopathy Treatments for Obesity That Works Best - 0 views
-
nirvana-india on 15 May 153 Naturopathy Treatments for Obesity That Works Best #Obesity, in recent times, has become a part and parcel of modern day existence-blame it on our erratic food habits and lifestyle. But now you can cure obesity too without gulping down capsules after.. website:http://nirvananaturopathy.quora.com/3-Naturopathy-Treatments-for-Obesity-That-Works-Best
-
nirvana-india on 15 May 153 Naturopathy Treatments for Obesity That Works Best #Obesity, in recent times, has become a part and parcel of modern day existence-blame it on our erratic food habits and lifestyle. But now you can cure obesity too without gulping down capsules after.. website:http://nirvananaturopathy.quora.com/3-Naturopathy-Treatments-for-Obesity-That-Works-Best
-
nirvana-india on 15 May 153 Naturopathy Treatments for Obesity That Works Best #Obesity, in recent times, has become a part and parcel of modern day existence-blame it on our erratic food habits and lifestyle. But now you can cure obesity too without gulping down capsules after.. website:http://nirvananaturopathy.quora.com/3-Naturopathy-Treatments-for-Obesity-That-Works-Best
![Naturopathy and Obesity- Naturopathic Approach for Helping Lose Weight](http://s3.amazonaws.com/diigo/thumbnail_160/8710315_258183257_17249999.jpg?AWSAccessKeyId=0R7FMW7AXRVCYMAPTPR2&Expires=1725619603&Signature=4cLO8g1zUBtczuGZhvhw0jhGDDc%3D)
Naturopathy and Obesity- Naturopathic Approach for Helping Lose Weight - 0 views
-
Naturopathy also uses proper exercises in order to reduce body weight. Naturopaths offering the best obesity treatments in India make use of effective workouts in order to increase resistance training and help you build more muscle website:http://nirvananaturopathy.blog.com/2015/03/12/naturopathy-and-obesity%E2%80%93-naturopathic-approach-for-helping-lose-weight/
-
Naturopathy also uses proper exercises in order to reduce body weight. Naturopaths offering the best obesity treatments in India make use of effective workouts in order to increase resistance training and help you build more muscle website:http://nirvananaturopathy.blog.com/2015/03/12/naturopathy-and-obesity%E2%80%93-naturopathic-approach-for-helping-lose-weight/
Boehringer to test obesity drug in three late-stage trials - 0 views
-
Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to 19 per cent weight loss after 46 weeks in a mid-stage trial. The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation. Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called glucagon that helps break down fat.
Experimental obesity drug has promising durability:Amgen - 0 views
-
Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.
Obesity: Just a Cosmetic Issue or a Serious Concern Dr Hemi Soneja - 0 views
-
Obesity rates have increased alarmingly in the last 10 years. It has become a rising epidemic in the world. It's not a cosmetic issue, anymore. Statistics suggest that the obesity rates have been increased alarmingly by more than 60% in the last 10 years. The condition has worsened so much that it has become a rising epidemic in the United States as well. So, it can't be considered a cosmetic issue, anymore. It is the second-leading cause of death across […]
Wegovy Approved to Prevent Heart Problems in Obese Adults | UK 2024 - 0 views
-
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.
Best Solutions & Treatment for Obesity in New York - 0 views
Novo Nordisk Launches Wegovy: UK Availability and Pricing - 0 views
-
Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through registered healthcare professionals. Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK. The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage. "We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access to and continuity of treatment for people living with obesity."
Best Treatment for Lipedema & Obesity & Fat Metabolism Disorder - 0 views
What Your College Didn't Tell You About Different Types of Obesity! - Pharma Health Online - 0 views
-
Being overweight can increase your chances of having bad cholesterol in your blood. Due to high cholesterol, a person may suffer from heart related diseases. According to doctor's research, a 10-pound increase in body weight produces 10 milligrams of cholesterol in the body. The body naturally needs cholesterol, and the liver makes the waxy substance to build the body's cells. Cholesterol is very useful for the body to produce vitamin D, which is essential for a healthy immune system. Fat creates triglycerides, which build up in our liver, creating too many triglycerides, which lead to the possibility of high cholesterol. If there is too much LDL (low-density lipoprotein) in the blood, which accumulates fat, this waxy substance can clog your arteries, leading to a heart attack or stroke. Research results show that low-liquid fructose can significantly affect glucose metabolism and lead to metabolic syndrome and fatty liver syndrome. Metabolic syndrome also includes type 2 diabetes, high blood pressure, and heart disease. The best treatment for reducing obesity is to use OTC obesity medications, such as Phentermine 37.5-mg, which you can easily buy from Pharma Health online.
Eli Lilly Mounjaro KwikPen Hits the UK:Transform Your Health - 0 views
-
Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.
Wegovy pioneers aim to jump on obesity market - 0 views
-
Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.
Zealand Pharma and Boehringer Ingelheim's weight-loss drug - 0 views
-
Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market. In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks. Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing. The enormous demand for weight-loss treatments such as Novo Nordisk's Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.
Erectile Dysfunction : 5 Natural Ways to Overcome ED - 0 views
-
Erectile dysfunction is a very common form of medical condition that occurs in males over time. Usually, this problem is found in people who take too much medication, and ED is probably a side effect of any one of them. However, in seventy-five percent of males, the cause of erectile dysfunction is unknown, and finding the accurate reason for it is very complex. It can be a result of any neural complications, diabetes, or any surgeries that include the prostate of our body. ED can also be treated by using a vacuum device and surgeries on the private parts. However, it can be eradicated completely without any surgeries, and here are some tips that will help you in overcoming erectile dysfunction without surgery and lead a happy life. DO EXERCISE Exercise is a great way to overcome any health issues, and also to safeguard yourself from health issues in the future. Physical activity also helps you in controlling obesity, which is one of the reasons behind ED. By not doing regular exercises, you expose yourself to various cardiovascular problems, which contribute to ED. Studies show that light aerobic exercise for 30-40 minutes a day for at least four times a week for at least 6 months has considerably reduced ED in people. STAY SLIM Studies have shown that a person who has a waist near 42 inches is more likely to suffer from ED than a person with a waistline of 32 inches. Therefore, if you are obese it's time that you lose some weight. Excessive fat in the body is the birthplace of various diseases. Obesity is also responsible for vascular problems and diabetes which are two primary causes of ED.
Mounjaro: New Diabetes Medicine Approved for Weight Loss - 0 views
-
A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.